A retrospective study of Ganoderma Lucidum Spore Powder for patients with epilepsy (2018)
Medicine (Baltimore). 2018 Jun; 97(23): e10941.
This study firstly investigated the feasibility effect and safety of Ganoderma Lucidum Spore Powder (GLSP) for treating patients with epilepsy.
Eighteen eligible patients with epilepsy were included. They all received GLSP treatment for a total of 8 weeks. The primary outcome included weekly seizure frequency. The secondary outcomes consisted of each seizure episode, and quality of life, measured by the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), as well as the adverse events (AEs).
After treatment, GLSP can significant reduce the weekly seizure frequency, compared with it before the treatment (P = .04). However, GLSP did not exert promising effect in each seizure episode (P = .13), and quality of life, measured by the QOLIE-31 scale (P = .11). Additionally, only minor AEs occurred during the treatment period.
The results of this study showed that GLSP may be effective for reducing the weekly seizure frequency. Further studies are still needed to warrant this result.
Hericium erinaceus has been considered as a medicinal mushroom since ancient times, but the scientific evidence for its effect on human health remains uncertain.
Hericium erinaceus, a well known edible mashroom, has numerous biological activities.
A double-blind, parallel-group, placebo-controlled trial was conducted in Japanese men and women aged 50-80 years who were diagnosed with mild cognitive impairment using a cognitive function scale based on the revised Hasegawa Dementia Scale (HDS-R) to examine the effect of oral consumption of erinaceus erinaceus on improving cognitive impairment.
Ganoderma lucidum has been widely used to treat various diseases, including cancer, diabetes, and neurasthenia in many Asian countries.
Top Quality Mushroom